Merck (MRK) Looks to Acquire Seagen (SGEN) - WSJ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Morgan Stanley Calls Seagen (SGEN) A Catalyst Driven Idea for 'Pivotal Padcev Data in 1L Bladder Cancer'
June 21, 2022 4:22 PM EDTMorgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $173.00 price target on Seagen (NASDAQ: SGEN).
The analyst comments "Padcev (Enfortumab vedotin or EV) is an antibody-drug conjugate designed for the treatment of cancer expressing Nectin-4 (a cell surface protein expressed on many... More
Seagen (SGEN) Seen Worth $200+ in a Takeover
June 21, 2022 12:53 PM EDTSeagen (NASDAQ: SGEN) is adding to Friday's gains as traders handicap the sale of the company following reports on Friday from the WSJ that Merck (NYSE: MRK) and others are eyeing a takeover of the biotech company.
Several analysts have weighed in on the potential deal and many view $200+ as the benchmark needed to get the deal done.
Oppenheimer analyst Jay Olson raised his price target on Seagen to $208 per share following the Merck speculation, which he thinks makes sense given recent dynamics, including:
1) SGEN and MRK... More
